{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T11:35:01Z","timestamp":1777721701671,"version":"3.51.4"},"reference-count":34,"publisher":"IMR Press","issue":"4","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Beijing Natural Science Foundation","award":["7254448"],"award-info":[{"award-number":["7254448"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation","doi-asserted-by":"crossref","award":["82500346"],"award-info":[{"award-number":["82500346"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science & Technology Commission","doi-asserted-by":"crossref","award":["Z241100009024048"],"award-info":[{"award-number":["Z241100009024048"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2023ZD0514600"],"award-info":[{"award-number":["2023ZD0514600"]}]},{"name":"Research Unit of Medical Science Research Management\/Basic and Clinical Research of Metabolic Cardiovascular Diseases, Chinese Academy of Medical Sciences","award":["2021RU003"],"award-info":[{"award-number":["2021RU003"]}]},{"name":"CAMS Special Project for Clinical and Translational Medicine Research","award":["2022-I2M-C&T-B-119"],"award-info":[{"award-number":["2022-I2M-C&T-B-119"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Background: Chronic obstructive pulmonary disease (COPD) and coronary artery disease (CAD) frequently occur together, with systemic inflammation linking these two conditions. Recently, the high-sensitivity C-reactive protein to albumin ratio (hsCAR) has been identified as a composite biomarker of inflammation and nutrition. Thus, this study aimed to examine the prognostic value of hsCAR in patients with COPD\u2013CAD undergoing percutaneous coronary intervention (PCI). Methods: In this cohort study, consecutive patients with COPD\u2013CAD who underwent PCI between 2014 and 2019 were enrolled and categorized into tertiles by hsCAR values. The primary endpoint was major adverse cardiac events (MACEs), including cardiac death, target vessel revascularization (TVR), and nonfatal myocardial infarction (MI). Patients underwent a follow-up for up to 4 years, and the incidence of MACEs was compared between the hsCAR groups using Kaplan\u2013Meier curves and Cox regression analyses. Results: A total of 262 patients were enrolled. Over a median follow-up of approximately 4 years, higher hsCAR levels were associated with an increased incidence of MACEs. The cumulative incidence of MACEs was highest in Group C (hsCAR \u22650.079). The incidence of MACEs was significantly higher in Group C than in Group A (19.5% vs. 5.7%; hazard ratio (HR) = 3.27, 95% confidence interval (CI): 1.08\u20139.86; p = 0.035). Receiver operating characteristic (ROC) curve analysis confirmed the associated discriminatory ability (area under the curve (AUC) = 0.651; p = 0.004). Restricted cubic spline (RCS) analysis showed a linear increase in the risk of MACEs as the absolute value of hsCAR exceeded 0.0446. Subgroup analyses revealed consistent associations across strata, with no significant interactions. Conclusion: Elevated baseline hsCAR is an independent predictor of long-term MACEs in patients with COPD\u2013CAD undergoing PCI. As an inexpensive and readily available biomarker, hsCAR could be used for post-PCI risk stratification to guide targeted secondary prevention in this high-risk population.<\/jats:p>","DOI":"10.31083\/rcm46633","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:31:56Z","timestamp":1777458716000},"source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Outcomes After Percutaneous Coronary Intervention According to the High-Sensitivity C-Reactive Protein-to-Albumin Ratio in Patients With Chronic Obstructive Pulmonary Disease in China"],"prefix":"10.31083","volume":"27","author":[{"given":"Yueyue","family":"Cao","sequence":"first","affiliation":[{"name":"Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, 100191 Beijing, China"},{"name":"Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, Peking University, 100191 Beijing, China"},{"name":"State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, 100191 Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yicheng","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, 100191 Beijing, China"},{"name":"Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, Peking University, 100191 Beijing, China"},{"name":"State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, 100191 Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, 100191 Beijing, China"},{"name":"Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, Peking University, 100191 Beijing, China"},{"name":"State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, 100191 Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, 100191 Beijing, China"},{"name":"Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, Peking University, 100191 Beijing, China"},{"name":"State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, 100191 Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, 100191 Beijing, China"},{"name":"Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, Peking University, 100191 Beijing, China"},{"name":"State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, 100191 Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, 100191 Beijing, China"},{"name":"Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, Peking University, 100191 Beijing, China"},{"name":"State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, 100191 Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9712-803X","authenticated-orcid":true,"given":"Yi-Da","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, 100191 Beijing, China"},{"name":"Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, Peking University, 100191 Beijing, China"},{"name":"State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, 100191 Beijing, China"},{"name":"Research Unit of Medical Science Research Management\/Basic and Clinical Research of Metabolic Cardiovascular Diseases, Chinese Academy of Medical Sciences, 100191 Beijing, China"},{"name":"University of Health and Rehabilitation Sciences, 266000 Qingdao, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4438-845X","authenticated-orcid":true,"given":"Yitian","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, 100191 Beijing, China"},{"name":"Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, Peking University, 100191 Beijing, China"},{"name":"State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, 100191 Beijing, China"},{"name":"Research Unit of Medical Science Research Management\/Basic and Clinical Research of Metabolic Cardiovascular Diseases, Chinese Academy of Medical Sciences, 100191 Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16242","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. Journal of the American College of Cardiology. 2020; 76: 2982\u20133021.","DOI":"10.1016\/j.jacc.2020.11.010"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Roversi S, Fabbri LM, Sin DD, Hawkins NM, Agust\u00ed A. Chronic Obstructive Pulmonary Disease and Cardiac Diseases. An Urgent Need for Integrated Care. American Journal of Respiratory and Critical Care Medicine. 2016; 194: 1319\u20131336.","DOI":"10.1164\/rccm.201604-0690SO"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Ruvuna L, Sood A. Epidemiology of Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine. 2020; 41: 315\u2013327.","DOI":"10.1016\/j.ccm.2020.05.002"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Chen H, Luo X, Du Y, He C, Lu Y, Shi Z, et al. Association between chronic obstructive pulmonary disease and cardiovascular disease in adults aged 40 years and above: data from NHANES 2013-2018. BMC Pulmonary Medicine. 2023; 23: 318.","DOI":"10.1186\/s12890-023-02606-1"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Brassington K, Selemidis S, Bozinovski S, Vlahos R. Chronic obstructive pulmonary disease and atherosclerosis: common mechanisms and novel therapeutics. Clinical Science (London, England: 1979). 2022; 136: 405\u2013423.","DOI":"10.1042\/CS20210835"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Wang JJ. Risk of Coronary Heart Disease in People with Chronic Obstructive Pulmonary Disease: A Meta-Analysis. International Journal of Chronic Obstructive Pulmonary Disease. 2021; 16: 2939\u20132944.","DOI":"10.2147\/COPD.S331505"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Yang HM, Ryu MH, Carey VJ, Kinney GL, Hokanson JE, Dransfield MT, et al. Chronic Obstructive Pulmonary Disease Exacerbations Increase the Risk of Subsequent Cardiovascular Events: A Longitudinal Analysis of the COPDGene Study. Journal of the American Heart Association. 2024; 13: e033882.","DOI":"10.1161\/JAHA.123.033882"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Therapeutic Advances in Respiratory Disease. 2018; 12: 1753465817750524.","DOI":"10.1177\/1753465817750524"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"King PT. Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer. Clinical and Translational Medicine. 2015; 4: 68.","DOI":"10.1186\/s40169-015-0068-z"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Oemrawsingh RM, Cheng JM, Akkerhuis KM, Kardys I, Degertekin M, van Geuns RJ, et al. High-sensitivity C-reactive protein predicts 10-year cardiovascular outcome after percutaneous coronary intervention. EuroIntervention: Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2016; 12: 345\u2013351.","DOI":"10.4244\/EIJY15M07_04"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Nillawar AN, Joshi KB, Patil SB, Bardapurkar JS, Bardapurkar SJ. Evaluation of HS-CRP and Lipid Profile in COPD. Journal of Clinical and Diagnostic Research: JCDR. 2013; 7: 801\u2013803.","DOI":"10.7860\/JCDR\/2013\/5187.2943"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Zheng Y, Qi Y, Seery S, Yang J, Li C, Wang W, et al. Elevated HsCRP in Chronic Obstructive Pulmonary Disease: A Prospective Study of Long-Term Outcomes After Percutaneous Coronary Intervention. International Journal of Chronic Obstructive Pulmonary Disease. 2022; 17: 2517\u20132528.","DOI":"10.2147\/COPD.S380194"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Zhu L, Chen M, Lin X. Serum albumin level for prediction of all-cause mortality in acute coronary syndrome patients: a meta-analysis. Bioscience Reports. 2020; 40: BSR20190881.","DOI":"10.1042\/BSR20190881"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Shen S, Xiao Y. Association Between C-Reactive Protein and Albumin Ratios and Risk of Mortality in Patients with Chronic Obstructive Pulmonary Disease. International Journal of Chronic Obstructive Pulmonary Disease. 2023; 18: 2289\u20132303.","DOI":"10.2147\/COPD.S413912"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Yang X, Yang X, Yang J, Wen X, Wu S, Cui L. High levels of high-sensitivity C reactive protein to albumin ratio can increase the risk of cardiovascular disease. Journal of Epidemiology and Community Health. 2023; 77: 721\u2013727.","DOI":"10.1136\/jech-2023-220760"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Yang J, Li C, Zheng Y, Gao J, Liu YP, Wang JJ, et al. The Association Between High-Sensitivity C-Reactive Protein\/Albumin Ratio and Cardiovascular Prognosis in Patients Undergoing Percutaneous Coronary Intervention. Angiology. 2022; 73: 818\u2013826.","DOI":"10.1177\/00033197221110715"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Tehrani DM, Seto AH. Third universal definition of myocardial infarction: update, caveats, differential diagnoses. Cleveland Clinic Journal of Medicine. 2013; 80: 777\u2013786.","DOI":"10.3949\/ccjm.80a.12158"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Brener SJ, Ertelt K, Mehran R, Genereux P, Xu K, Witzenbichler B, et al. Predictors and impact of target vessel revascularization after stent implantation for acute ST-segment elevation myocardial infarction: lessons from HORIZONS-AMI. American Heart Journal. 2015; 169: 242\u2013248.","DOI":"10.1016\/j.ahj.2014.11.005"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. The European Respiratory Journal. 2019; 53: 1900164.","DOI":"10.1183\/13993003.00164-2019"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Ghariani A, Ben Abdessalem MA, Cheikh Sideya K, Fekih Romdhane A, Ben Ameur Z, Mosrati H, et al. Outcomes and prognostic factors of patients treated for in-stent restenosis: a retrospective single-center experience. The Egyptian Heart Journal: (EHJ): Official Bulletin of the Egyptian Society of Cardiology. 2022; 74: 42.","DOI":"10.1186\/s43044-022-00281-x"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Huang H, Yu Y, Chen L, Chen S, Tang R, Li Q, et al. Independent and joint effects of high-sensitivity c-reactive protein and hypoalbuminemia on long-term all-cause mortality among coronary artery disease: a prospective and multicenter cohort study. BMC Cardiovascular Disorders. 2021; 21: 613.","DOI":"10.1186\/s12872-021-02431-6"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Liu ZY, Tang JN, Cheng MD, Jiang LZ, Guo QQ, Zhang JC, et al. C-reactive protein-to-serum albumin ratio as a novel predictor of long-term outcomes in coronary artery disease patients who have undergone percutaneous coronary intervention: analysis of a real-world retrospective cohort study. Coronary Artery Disease. 2021; 32: 191\u2013196.","DOI":"10.1097\/MCA.0000000000001021"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Acet H, G\u00fczel T, Aslan B, Isik MA, Ertas F, Catalkaya S. Predictive Value of C-Reactive Protein to Albumin Ratio in ST-Segment Elevation Myocardial Infarction Patients Treated With Primary Percutaneous Coronary Intervention. Angiology. 2021; 72: 244\u2013251.","DOI":"10.1177\/0003319720963697"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Li J, Zhu P, Li Y, Yan K, Tang X, Xu J, et al. A novel inflammatory biomarker, high-sensitivity C-reactive protein-to-albumin ratio, is associated with 5-year outcomes in patients with type 2 diabetes who undergo percutaneous coronary intervention. Diabetology & Metabolic Syndrome. 2023; 15: 14.","DOI":"10.1186\/s13098-022-00977-9"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Cheng L, Meng Z, Wang Q, Jian Z, Fan P, Feng X, et al. The Usefulness of C-Reactive Protein to Albumin Ratio in the Prediction of Adverse Cardiovascular Events in Coronary Chronic Total Occlusion Undergoing Percutaneous Coronary Intervention. Frontiers in Cardiovascular Medicine. 2021; 8: 731261.","DOI":"10.3389\/fcvm.2021.731261"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Karaba\u011f Y, \u00c7a\u011fda\u015f M, Rencuzogullari I, Karakoyun S, Arta\u00e7 \u0130, \u0130li\u015f D, et al. Relationship between C-reactive protein\/albumin ratio and coronary artery disease severity in patients with stable angina pectoris. Journal of Clinical Laboratory Analysis. 2018; 32: e22457.","DOI":"10.1002\/jcla.22457"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Kamrani F, Rezaee A, Bigdeloo L, Naseh Mojdehi A, Darroudi S, Hossein Talebkhah M, et al. Concordant and discordant roles of remnant cholesterol and hs-CRP in cardiovascular disease; gender stratified analysis. Lipids in Health and Disease. 2025; 24: 211.","DOI":"10.1186\/s12944-025-02627-1"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Ishida M, Sakai C, Kobayashi Y, Ishida T. Cigarette Smoking and Atherosclerotic Cardiovascular Disease. Journal of Atherosclerosis and Thrombosis. 2024; 31: 189\u2013200.","DOI":"10.5551\/jat.RV22015"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Farmer HR, Wray LA, Haas SA. Race, Gender, and Socioeconomic Variations in C-Reactive Protein Using the Health and Retirement Study. The Journals of Gerontology. Series B, Psychological Sciences and Social Sciences. 2021; 76: 583\u2013595.","DOI":"10.1093\/geronb\/gbaa027"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Sinning C, Makarova N, V\u00f6lzke H, Schnabel RB, Ojeda F, D\u00f6rr M, et al. Association of glycated hemoglobin A1\u2062c levels with cardiovascular outcomes in the general population: results from the BiomarCaRE (Biomarker for Cardiovascular Risk Assessment in Europe) consortium. Cardiovascular Diabetology. 2021; 20: 223.","DOI":"10.1186\/s12933-021-01413-4"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Liu Y, Yang YM, Zhu J, Tan HQ, Liang Y, Li JD. Prognostic significance of hemoglobin A1c level in patients hospitalized with coronary artery disease. A systematic review and meta-analysis. Cardiovascular Diabetology. 2011; 10: 98.","DOI":"10.1186\/1475-2840-10-98"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Rannanheimo PK, Tiittanen P, Hartikainen J, Helin-Salmivaara A, Huupponen R, Vahtera J, et al. Impact of Statin Adherence on Cardiovascular Morbidity and All-Cause Mortality in the Primary Prevention of Cardiovascular Disease: A Population-Based Cohort Study in Finland. Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research. 2015; 18: 896\u2013905.","DOI":"10.1016\/j.jval.2015.06.002"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Zhang XL, Chi YH, Wang LF, Wang HS, Lin XM. Systemic inflammation in patients with chronic obstructive pulmonary disease undergoing percutaneous coronary intervention. Respirology (Carlton, Vic.). 2014; 19: 723\u2013729.","DOI":"10.1111\/resp.12295"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Tian Y, Liu H, Wang Y. Changes and significance of high-density lipoprotein A-I, A-II, and serum amyloid levels in patients with chronic obstructive pulmonary disease complicated by coronary heart disease. Clinical and experimental hypertension (New York, N.Y.: 1993). 2025; 47: 2524105.","DOI":"10.1080\/10641963.2025.2524105"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/4\/10.31083\/RCM46633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:32:55Z","timestamp":1777458775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/4\/10.31083\/RCM46633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"alternative-id":["S1530-6550(26)02632-0"],"URL":"https:\/\/doi.org\/10.31083\/rcm46633","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"article-number":"46633"}}